Indication
Dry Eye Disease
Administration
Ophthalmic Administration
Drops are in single-use containers; discard the single-use container immediately after using in each eye
Remove contact lenses before instilling eye drops; may be reinserted 15 minutes following administration
Adult Dose
Eye drop
Dry Eye Disease
Indicated for treatment of the signs and symptoms of dry eye disease (DED)
Instill 1 gtt q12hr into each eye
Child Dose
<17 years: Safety and efficacy not established
Mode of Action
The exact mechanism in dry eye disease is not known
Binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein bound on leukocytes, and blocks the interactions of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1)
ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease; LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues
In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells
Side Effect
>10%
Instillation site irritation (5-25%)
Dysgeusia (5-25%)
Reduced visual acuity (5-25%)
1-10%
Blurred vision (1-5%)
Conjunctival hyperemia (1-5%)
Eye irritation (1-5%)
Headache (1-5%)
Increased lacrimation (1-5%)
Eye discharge (1-5%)
Eye discomfort (1-5%)
Eye pruritus (1-5%)
Sinusitis (1-5%)
Pregnancy Category Note
Pregnancy
There are no available data regarding use in pregnant women to inform any drug-associated risks
Lactation
There are no data on the presence of lifitegrast in human milk; systemic exposure to lifitegrast from ocular administration is low